1 Zhang X,Zhang L,Tian C,et al.Genetic variants and risk of cervical cancer:epidemiological evidence,meta-analysis and research review.BJOG,2014,121:664-674. 2 Qin C,Chen X,Bai Q,et al.Factors associated with radiosensitivity of cervical cancer.Anticancer Res,2014,34:4649-4656. 3 Takashi N,Tatsuya O,Hitoshi I,et al.Current advancement in radiation therapy for uterine cervical cancer.J Radiat Res,2010,51:1-8. 4 Linam J,Yang LX.Recent developments in radiosensitization.Anticancer Res,2015,35:2479-2485. 5 Menon JU,Tumati V,Hsieh JT,et al.Polymeric nanoparticles for targeted radiosensitization of prostate cancer cells.J Biomed Mater Res A,2015,103:1632-1639. 6 Ghotra VP,Geldof AA,Danen EH.Targeted radiosensitization in prostate cancer.Curr Pharm Des,2013,19:2819-2828. 7 Skotland T,Iversen TG,Torgersen ML,et al.Cell-penetrating peptides:possibilities and challenges for drug delivery in vitro and in vivo.Molecules,2015,20:13313-13323. 8 Zhang T,Wu K,Ding C,et al.Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus.Oncotarget,2015,6:37782-37791. 9 Liu L,Xu C,Hsieh JT,et al .DAB2IP in cancer.Oncotarget,2015,7:3766-3776. 10 Chen H,Karam JA,Schultz R,et al.Cloning of mouse Dab2ip gene,a novel member of the RasGTPase-activating protein family and characterization of its regulatory region in prostate.DNA Cell Biol,2006,25:232-245. 11 Duan YF,Li DF,Liu YH,et al.Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.Hepatobiliary Pancreat Dis Int,2013,1:204-209. 12 Zhu JN,Wu KJ,Guan ZF,et al.DAB2IP expression in bladder transitional cell carcinoma and its correlation with clinical outcome.Sichuan Da Xue Xue Bao Yi Xue Ban,2014,45:591-594. 13 Wu K,Xie D,Zou Y,et al.The mechanism of DAB2IP in chemoresistance of prostate cancer cells,Clin Cancer Res,2013,19:4740-4749. 14 Xu Y,He J,Wang Y,et al.miR-889 promotes proliferation of esophageal squamous cell carcinomas through DAB2IP.FEBS Lett,2015,589:1127-1135. 15 Kong Z,Raghavan P,Xie D,et al.Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells.Int J Radiat Oncol Biol Phys,2010,78:1210-1218. 16 Kong Z,Xie D,Boike T,et al.Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation.Cancer Res,2010,70:2829-2839. 17 Liao H,Xiao Y,Hu Y,et al.MicroRNA-32 induces radioresistance by targeting DAB2IP and regulating autophagy in prostate cancer cells.Oncol Lett,2015,10:2055-2062. 18 Zhang T,Shen Y,Chen Y,et al.The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect.Int J Radiat Biol,2015,91:368-378. 19 Xie D,Gore C,Zhou J,et al.DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis.Proc Natl Acad Sci U S A,2009,106:19878-19883. 20 Zhang H,Zhang R,Luo Y,et al.AIP1/DAB2IP,a novel member of the Ras-GAP family,transduces TRAF2-induced ASK1-JNK activation.J BIOL CHEM,2004,279:44955-44965. 21 Karin M,Gallagher E.TNFR signaling:ubiquitin-conjugated TRAFfic signals control stop-and-go for MAPK signaling complexes.Immunol Rev,2009,228:225-240. 22 Wu K,Wang B,Chen Y,et al.DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling.Cell Signal,2015,27:2515-2523. 23 Chen H,Pong RC,Wang Z,et al.Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia:cloning and characterization.Genomics,2002,79:573-581. 24 Zhou J,Ning Z,Wang B,et al.DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis.Cell Death Dis,2015,6:1955-1955.
